Variety of suitable patients: CDEC mentioned the uncertainty in the amount of sufferers with moderately severe to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are categorised as owning moderate or reasonable condition can have a critical bleedin… Read More